Biotech News

Medpace Holdings, Inc. Reports Second Quarter 2025 Results

Medpace (MEDP)Medpace2026-06-25 13:46 ESTEarnings

Revenue of $603.3 million in the second quarter of 2025 increased 14.2% from revenue of $528.1 million for the comparable prior-year period, representing a backlog conversion rate of 21.2%. Net new business awards were $620.5 million in the second quarter of 2025, representing an increase of 12.6%

Open original release

Related news

Medpace

Medpace is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

Stock data

Close
Market cap
Exchange
NASDAQ
Sector
Biotechnology
Location
United States